15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 17 firms covering Cytokinetics Inc, 16 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $84.00 to $140.00, a moderate spread. The average target of $108.38 sits 44% above the current $75.37. The rating mix has stayed broadly stable, with Buy-side ratings easing from 18 to 16 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.41 next quarter toward $-4.45 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 ratings
Strong Buy
Strong Buy00%
Buy1694%
Hold16%
Sell00%
Strong Sell00%
Based on 17 analysts giving stock ratings to Cytokinetics Inc.
As of Sep, 16 of 17 firms rate CYTK a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CYTK EPS & revenue forecast
EPS · NEXT QUARTER
$-1.41
Range $-1.76 – $-1.02 · 16 analysts · -6% YoY
Next period, 16 analysts expect Cytokinetics Inc to earn $-1.41 a share (range $-1.76 – $-1.02), versus $-1.50 a year earlier. Full-year consensus is $-5.94, growing to $-4.45 the year after.
REVENUE · NEXT QUARTER
$58.3M
Range $33.8M – $85.2M · 16 analysts · +229% YoY
Revenue is expected to reach $58.3M (range $33.8M – $85.2M), +228.5% year-over-year. Full-year consensus is $149.8M, rising to $424.8M next year.
Top analysts covering Cytokinetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CYTK.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Buy
$103.00+36.7% to target
Overall win rate
64%
+ Follow
#2
Jason Butler
JMP Securities · Rank #31
Buy
$110.00+45.9% to target
Overall win rate
53%
+ Follow
#3
Leonid Timashev
RBC Capital · Rank #33
Buy
$112.00+48.6% to target
Overall win rate
48%
+ Follow
#4
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$146.00+93.7% to target
Overall win rate
50%
+ Follow
#5
Serge Belanger
Needham · Rank #105
Buy
$112.00+48.6% to target
Overall win rate
48%
+ Follow
CYTK stock forecast FAQ
What is CYTK's average 12-month price target?+
The 16 analysts with a live target average $108.38 for Cytokinetics Inc over the next 12 months, ranging from a $140.00 high to a $84.00 low.
Is CYTK stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 17 analyst ratings, 16 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CYTK?+
The Street-high target is $140.00 (HC Wainwright & Co.), and the Street-low is $84.00 (Leerink Partners). The average of all 16 active targets is $108.38.
How many Wall Street analysts cover CYTK?+
17 analysts have an active rating on Cytokinetics Inc, and 16 firms carry a live 12-month price target.
Who is the most accurate analyst covering CYTK?+
Among analysts who currently cover CYTK, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Buy with a $103.00 target.
What is Cytokinetics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.41 per share (range $-1.76 – $-1.02) across 16 analysts. Full-year EPS is projected at $-5.94, rising to $-4.45 the following year.
How much revenue is Cytokinetics Inc expected to report next quarter?+
Consensus revenue is $58.3M (range $33.8M – $85.2M). Full-year revenue is projected at $149.8M, growing to $424.8M next year.
Have analysts been upgrading or downgrading CYTK lately?+
As of Sep, 16 of 17 firms rate CYTK a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CYTK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
